Fondo Bibliografico Internacional Julio 2001
Transplante hepático
Kamel IR, Kruskal JB, Raptopoulos IR. Kamel, JB. Kruskal,
V. Raptopoulos V. Imaging for Right Lobe Living Donor Liver Transplantation.
Sem Liv Dis 2001; 21: 271-82.
Selección y evaluación radiológica
del donante vivo de lóbulo hepático derecho.
Samuel D. Liver transplantation and hepatitis B virus infection:
the situation seems to be under control, but the virus is still there. Journal
of Hepatology 2001; 34: 943-5.
Editorial.
Marzan A, Salizzoni M, Debernardi-Venon W, Smedile A, Franchello
A, Ciancio A, Gentilcore E, Piantino P, Barbui AM, David E, Negro F, Rizzetto
M. Prevention of hepatitis B virus recurrence after liver transplantation
in cirrhotic patients treated with lamivudine and passive immunoprophylaxis.
Journal of Hepatology 2001; 34: 903-10.
La profilaxis combinada con lamivudina y gammaglobulina
hiperinmune disminuye el riesgo de recurrencia de la hepatitis B tras el trasplante
hepático.
Rosenau J, Bahr MJ, Tillmann HL, Trautwein C, Klempnauer J,
Manns MP, Boker KHW. Lamivudine and low-dose hepatitis B immune globulin for
prophylaxis of hepatitis B reinfection after liver transplantation possible
role of mutations in the YMDD motif prior to transplantation as a risk factor
for reinfection. Journal of Hepatology 2001; 34: 895-902.
La profilaxis combinada con gammaglobulina hiperinmune
y lamivudina es eficaz, en los pacientes con infección controlada,
por la resistencia que proporciona la lamivudina, administrada antes del trasplante,
a la reinfección.
Naoumov NV, Lopes AR, Burra P, Caccamo L, Iemmolo RM, de Man
RA, Bassendine M, O'Grady JG, Portmann BC, Anschuetz G, Barrett CA, Williams
R, Atkins M. Randomized trial of lamivudine versus hepatitis B immunoglobulin
for long-term prophylaxis of hepatitis B recurrence after liver transplantation.
Journal of Hepatology 2001; 34: 888-94.
La sustitución de gammaglobulina hiperinmune
por lamivudina previene la recurrencia de la hepatitis B en los pacientes
con bajo riesgo y representa una reducción del coste de la profilaxis
a largo plazo.
Madhotra R, Carter TD, Willner I, Reuben A. Reversible flaccid
paraplegia after orthotopic liver transplantation. American Journal of Gastroenterology
2001; 96: 1943-4.
Carta.
Neuhaus P, Klupp J, Michael Langrehr J. mTOR inhibitors: An
overview. Liver Transplantation 2001; 7: 473-84.
Eficacia de los diferentes inmunomoduladores para
prevenir el rechazo agudo.
Trotter JF, Talamantes M, McClure M, Wachs M, Bak T, Trouillot
T, Kugelmas M, Everson GT, Kam I. Right hepatic lobe donation for living donor
liver transplantation: Impact on donor quality of life. Liver Transplantation
2001; 7: 485-93.
Elevada incidencia de sintomatología en los
donantes vivos de hígado.
Caplan Al. Proceed with caution: Live living donation of lobes
of liver for transplantation. Liver Transplantation 2001; 7: 494-5.
Editorial.
Hughes VF, Melvin DG, Niranjan M, Graeme A, Alexander M, Trull
AK. Clinical validation of an artificial neural network trained to identify
acute allograft rejection in liver transplant recipients. Liver Transplantation
2001; 7: 496-03.
Validación clínica de un método
para identificar el rechazo agudo.
Fontana RJ, Hann HWL, Wright T, Everson G, Baker A, Schiff
ER, Riely C, Anschuetz G, Riker-Hopkins M, Brown N, and for the US Lamivudine
Compassionate Use Study Group. A multicenter study of lamivudine treatment
in 33 patients with hepatitis B after liver transplantation. Liver Transplantation
2001; 7: 504-10.
El tratamiento prolongado con lamivudina es seguro
y eficaz en los pacientes trasplantados con recurrencia de la infección
por virus B.
Mutimer D. Lamivudine for hepatitis B after liver transplantation.
Liver Transplantation 2001; 7: 511-2.
Editorial.
Yu AS, Vierling JM, Colquhoun SD, Arnaout WS, Chan CK, Khanafshar
E, Geller SA, Nichols WS, Fong TL. Transmission of hepatitis B infection from
hepatitis B core antibody-positive liver allografts is prevented by lamivudine
therapy. Liver Transplantation 2001; 7: 513-5.
La lamivudina permite la utilización de donantes
HbcAg+ para los receptores HbsAg- y consecuentemente aumenta el número
de donantes.
Rizzetto M. Transmission of hepatitis B infection from hepatitis
B core antibody-positive livers: Background and prevention. Liver Transplantation
2001; 7: 518-20.
Editorial.
Yoshida EM, Buczkowski AK, Giulivi A, Zou S, Forrester LA.
A cross-sectional study of SEN virus in liver transplant recipients. Liver
Transplantation 2001; 7: 521-5.
Elevada prevalencia de virus SEN en los receptores
de trasplante hepático.
Neal DAJ, Gimson A, Gibbs P, Alexander G. Beneficial effects
of converting liver transplant recipients from cyclosporine to tacrolimus
on blood pressure, serum lipids, and weight. Liver Transplantation 2001; 7:
533-9.
Los factores de riesgo cardiovascular son los indicadores
de supervivencia a largo plazo en los trasplantados con rechazo bajo control.
Pirenne J, Van Gelder F, Coosemans W, Aerts R, Gunson B, Koshiba
T, Fourneau I, Mirza D, Van Steenbergen W, Fevery J, Nevens F, McMaster P.
Type of donor aortic preservation solution and not cold ischemia time is a
major determinant of biliary strictures after liver transplantation. Liver
Transplantation 2001; 7: 540-5.
Una solución preservante de baja viscosidad
se asocia a un menor daño isquémico de la vía biliar.
Shapiro RS, Fishbein T, Schwartz M, Miller CM. Use of intraoperative
Doppler ultrasound to diagnose hepatic venous obstruction in a right lobe
living donor liver transplant. Liver Transplantation 2001; 7: 547-50.
La vena hepática es el talón de Aquiles
para el trasplante de lóbulo hepático derecho.
Ghobrial RM, Hsieh CB, Lerner S, Winters S, Nissen N, Dawson
S, Amersi F, Chen P, Farmer D, Yersiz H, Busuttil RW. Technical challenges
of hepatic venous outflow reconstruction in right lobe adult living donor
liver transplantation. Liver Transplantation 2001; 7: 551-5.
Hurtova M, Duclos-Vallée JC, Johanet C, Emile JF, Roque-Afonso
AM, Feray C, Bismuth E, Samuel D. Successful tacrolimus therapy for a severe
recurrence of type 1 autoimmune hepatitis in a liver graft recipient. Liver
Transplantation 2001; 7: 556-8.
Utilidad del tacrolimus para prevenir la recurrencia
de la hepatitis autoinmune.
Kobashigawa JA. Statins as immunosuppressive agents. Liver
Transplantation 2001; 7: 559-61.
Ramírez P, Yelamos J, Parrilla P, Chávez
R. Hepatic xenotransplantation will benefit from strategies aimed to reduce
complement activation. Liver Transplantation 2001; 7: 562
Carta al editor.
